AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Reduced Heart Failure Risk Associated with the Sodium-Glucose Cotransporter 2 Inhibitor Among US Veterans with Early-Onset Type 2 Diabetes

By Lin Y, Zu Y, Yoshida Y

Background: Adults with early-onset type 2 diabetes (T2D), defined as diagnosis before age 45 years, account for up to 20% of the adult T2D population and have a substantially higher risk of cardiovascular disease, including heart failure (HF), compared with those with later-onset T2D. Although sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated risk reduction in HF in older adults with T2D, evidence in populations with early-onset T2D remains limited. Objective: To compare the risk of HF between SGLT2i and sulfonylurea (SU) users among veterans with early-onset T2D. Methods: We conducted a retrospective cohort study of 135,566 veterans with T2D diagnosed before age 45 years using national Veterans Affairs electronic health records from 2000 to 2025. We identified 5224 eligible SGLT2i users (mean age 39.8 years, 48.6% White) and 24502 SU users (mean age 39.9 years, 44.8% White). We excluded individuals with medication exposure <2 years and those with prevalent HF and major adverse cardiovascular events before or on the index date. Incident HF was identified by ICD-9/10 codes: 428.X, I50.X. Follow-up began at SGLT2i or SU treatment initiation and continued until the earliest of outcome occurrence, death, loss to follow-up, or 4 or 8 years after the index date. Kaplan-Meier methods with log-rank tests were used to compare event-free survival, and Cox proportional hazards models were used to estimate hazard ratios (HRs) for HF risk associated with SGLT2i versus SU use. Covariates included age, sex, race/ethnicity, T2D duration, BMI, HbA1c, total cholesterol, triglycerides, smoking, hyperlipidemia, hypertension, atrial fibrillation, chronic kidney disease, chronic liver disease, and major depressive disorders. Results: At 4 years, the SGLT2i group had 30 HF (99.4% survival) compared with 167 (99.3% survival) events in the SU group. At 8 years, corresponding event counts were 35 (99.3% survival) in the SGLT2i group versus 554 (97.7% survival) in the SU group ( P< 0.05). Compared with SU users, SGLT2i users had a nonsignificantly lower risk of HF over 4 years (HR 0.84, 95% CI 0.51-1.39), but a significantly lower HF risk over 8 years (HR 0.64, 95% CI 0.43-0.96). Conclusions: Among veterans with early-onset T2D, SGLT2i use was associated with a significantly lower risk of HF compared with SU use over 8 years of follow-up. The magnitude of benefit was comparable to prior clinical trial estimates in adults with later-onset T2D (HRs ranging from 0.65 to 0.85), supporting the potential HF benefit of SGLT2i use in this high-risk population.

doi.org/10.1161/circ.154.suppl_1.4950Populations

AgingResearch.News